{"doc_type":"other","party_a_name":"Dova Pharmaceuticals, Inc.","party_b_name":"Valeant Pharmaceuticals North America LLC","effective_date":"2018-09-26","term_length":48,"governing_law":"unknown","termination_notice_days":null,"liability_cap":"No monetary liability cap stated; excludes consequential/incidental/indirect/special/punitive damages, with carve-outs for indemnification and confidentiality breaches.","non_solicit_clause_present":true,"data_transfer_outside_uk_eu":"unknown","risk_level":"medium","risk_explanation":"The agreement contains broad mutual indemnities and no explicit monetary cap on liability, which can create open-ended exposure for a small vendor. It does include a mutual waiver of consequential damages, but that waiver does not limit third-party indemnity obligations or confidentiality-breach damages. Termination-for-convenience notice is redacted, adding uncertainty around exit rights and operational risk."}